← The Wire
RPRXNasdaq
Royalty Pharma plc
Pharmaceutical Preparations · X0 · CIK 1802768
Largest buyer of biopharmaceutical royalties, funding innovation by acquiring rights to future sales of therapies
⚡ Elevated coverage
$24.32B
Market cap
$57.09
Last close
+1.5%
1D
+6.6%
5D
2.5M
Volume
Price · last 39 sessions+13.7%
May 4L $50.20 · H $57.09Jun 29
138
Total filings
Jun 4, 2026
Last filing
12/31
Fiscal year end
SC 13D/ASC 13D/AJun 16, 20268-KShareholder VoteJun 4, 20268-KMaterial Agreement · New Debt / ObligationMay 28, 202610-Q10-QMay 6, 20268-KResults of OperationsMay 6, 20268-KReg FD DisclosureApr 13, 2026DEFA14ADEFA14AApr 10, 2026DEF 14ADEF 14AApr 10, 2026SC 13D/ASC 13D/AFeb 20, 202610-K10-KFeb 11, 20268-KResults of OperationsFeb 11, 20268-KExecutive ChangeDec 22, 20258-KReg FD DisclosureDec 22, 202510-Q10-QNov 5, 20258-KResults of OperationsNov 5, 20258-KMaterial Agreement · Company UpdateSep 16, 20258-KExecutive ChangeAug 13, 202510-Q10-QAug 6, 20258-KResults of OperationsAug 6, 20258-KExecutive ChangeJul 17, 20258-KExecutive Change · Material AgreementMay 19, 20258-KShareholder VoteMay 12, 202510-Q10-QMay 8, 20258-KResults of OperationsMay 8, 2025DEFA14ADEFA14AApr 11, 20258-KMaterial AgreementApr 11, 2025DEFA14ADEFA14AApr 10, 20258-KExecutive ChangeApr 10, 2025DEFA14AFORM DEFA14AMar 5, 202510-K10-KFeb 12, 20258-KResults of OperationsFeb 11, 2025DEFA14AFORM DEFA14AJan 17, 2025DEFA14AFORM DEFA14AJan 16, 2025425FORM 425Jan 15, 2025DEFA14ADEFA14AJan 13, 20258-KReg FD DisclosureJan 13, 2025DEFA14AFORM DEFA14AJan 10, 20258-KMaterial Agreement · Equity IssuanceJan 10, 20258-KResults of OperationsJan 10, 20258-KMaterial Agreement · Bylaw AmendmentDec 31, 202410-Q10-QNov 6, 20248-KResults of OperationsNov 6, 20248-KReg FD DisclosureSep 27, 202410-Q10-QAug 8, 20248-KResults of OperationsAug 8, 20248-KReg FD DisclosureAug 7, 20248-KCompany UpdateJun 20, 20248-KMaterial Agreement · New Debt / ObligationJun 10, 20248-KShareholder VoteJun 6, 2024424B5424B5Jun 4, 20248-KMaterial AgreementJun 4, 2024424B5424B5Jun 3, 20248-KCompany UpdateMay 29, 202410-Q10-QMay 9, 20248-KResults of OperationsMay 9, 2024DEFA14ADEFA14AApr 25, 2024DEF 14ADEF 14AApr 25, 202410-K10-KFeb 15, 20248-KResults of OperationsFeb 15, 20248-KCompany UpdateFeb 6, 20248-KResults of OperationsJan 8, 20248-KMaterial Agreement · New Debt / ObligationDec 27, 20238-KCompany UpdateDec 27, 20238-KCompany UpdateNov 16, 202310-Q10-QNov 8, 20238-KResults of OperationsNov 8, 20238-KNew Debt / ObligationOct 19, 202310-Q10-QAug 8, 20238-KResults of OperationsAug 8, 20238-KShareholder VoteJun 23, 202310-Q10-QMay 9, 20238-KResults of OperationsMay 9, 2023DEFA14ADEFA14AApr 27, 2023DEF 14ADEF 14AApr 27, 20238-KBylaw AmendmentMar 28, 20238-KReg FD DisclosureMar 15, 202310-K10-KFeb 15, 20238-KResults of OperationsFeb 15, 20238-KResults of OperationsJan 9, 20238-KMaterial ImpairmentDec 1, 2022
Insider Activity
In the 90 days to Mar 23, 2026: 2 sold $25.3M.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 23, 2026 | Coyne Terrance P.EVP & CFO | Sell | 32,916 | $45.53 | $1.5M |
| Mar 23, 2026 | Coyne Terrance P.EVP & CFO | Sell | 1,875 | $45.53 | $85K |
| Mar 2, 2026 | Coyne Terrance P.EVP & CFO | Sell | 22,487 | $46.67 | $1.0M |
| Mar 2, 2026 | Coyne Terrance P.EVP & CFO | Sell | 10,429 | $47.01 | $490K |
| Mar 2, 2026 | Coyne Terrance P.EVP & CFO | Sell | 1,292 | $46.67 | $60K |
| Mar 2, 2026 | Coyne Terrance P.EVP & CFO | Sell | 583 | $47.01 | $27K |
| Feb 23, 2026 | Coyne Terrance P.EVP & CFO | Sell | 32,916 | $45.32 | $1.5M |
| Feb 23, 2026 | Coyne Terrance P.EVP & CFO | Sell | 1,875 | $45.32 | $85K |
| Feb 4, 2026 | Coyne Terrance P.EVP & CFO | Sell | 19,076 | $43.29 | $826K |
| Feb 4, 2026 | Coyne Terrance P.EVP & CFO | Sell | 1,087 | $43.29 | $47K |
| Feb 3, 2026 | Coyne Terrance P.EVP & CFO | Sell | 108,759 | $42.84 | $4.7M |
| Feb 3, 2026 | Coyne Terrance P.EVP & CFO | Sell | 6,195 | $42.84 | $265K |
| Feb 2, 2026 | Coyne Terrance P.EVP & CFO | Sell | 102,581 | $42.08 | $4.3M |
| Feb 2, 2026 | Coyne Terrance P.EVP & CFO | Sell | 5,843 | $42.08 | $246K |
| Jan 30, 2026 | Urist MarshallEVP, Research & Investments | Sell | 20,000 | $41.09 | $822K |
| Jan 23, 2026 | Urist MarshallEVP, Research & Investments | Sell | 20,000 | $40.26 | $805K |
| Jan 20, 2026 | Coyne Terrance P.EVP & CFO | Sell | 65,832 | $39.35 | $2.6M |
| Jan 20, 2026 | Coyne Terrance P.EVP & CFO | Sell | 3,750 | $39.35 | $148K |
| Jan 16, 2026 | Urist MarshallEVP, Research & Investments | Sell | 20,000 | $39.52 | $790K |
| Jan 9, 2026 | Urist MarshallEVP, Research & Investments | Sell | 20,000 | $40.78 | $816K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
In the News
⚡ Elevated coverageCoverage (30d): 1 reputable article.
Reputable outlets only (Reuters, WSJ, CNBC, Barron's, and peers). More on Google News ↗
Similar companies
Comparable business profile · signals at a glance